Pharma Mar (XMAD:PHM) Forward PE Ratio : 0.00 (As of May. 22, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Forward PE Ratio?

Pharma Mar's Forward PE Ratio for today is 0.00.

Pharma Mar's PE Ratio without NRI for today is 418.84.

Pharma Mar's PE Ratio for today is 333.52.

Pharma Mar Forward PE Ratio Historical Data

The historical data trend for Pharma Mar's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Forward PE Ratio Chart

Pharma Mar Annual Data

Trend

2015-12

2016-12

2017-12

2018-12

2019-03

Forward PE Ratio

62.89

303.03

20.33

40.32

53.76

Pharma Mar Quarterly Data
	2015-12	2016-03	2016-06	2016-09	2016-12	2017-03	2017-06	2017-09	2017-12	2018-03	2018-06	2018-09	2018-12	2019-03
Forward PE Ratio	62.89	23.15	23.42	312.50	303.03	114.94	151.52	131.58	20.33	62.50	58.48	56.50	40.32	53.76

Competitive Comparison of Pharma Mar's Forward PE Ratio

For the Biotechnology subindustry, Pharma Mar's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Mar's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Forward PE Ratio falls into.

Pharma Mar Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Pharma Mar (XMAD:PHM) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Pharma Mar Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Mar (XMAD:PHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

PHMMF:USA PHMe:UK 0RC6:UK

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.